Literature DB >> 11196160

Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy.

E S Abdel-Hady1, P Martin-Hirsch, M Duggan-Keen, P L Stern, J V Moore, G Corbitt, H C Kitchener, I N Hampson.   

Abstract

Topical 5-aminolevulinic acid-based photodynamic therapy (PDT) has produced complete response rates of >90% for nonmelanoma skin carcinomas, which are mostly human papillomavirus (HPV) negative. Using a similar treatment protocol, we observed a short-term response in only one third (10 of 32) of high-grade vulval intraepithelial neoplasia (VIN 2-3) lesions. Unifocal lesions were found more responsive than multifocal and pigmented lesions. Animal model studies have suggested that long-term PDT response involves an immune reaction in which CTLs play a crucial role. In this study, we have assessed: (a) HPV infection; (b) HLA expression; and (c) immune infiltrating cells in VIN biopsies from responders and nonresponders to determine whether these factors may limit response to topical 5-aminolevulinic acid-based PDT. Tissues from normal vulva (n = 9), vulval carcinoma (n = 11), and VIN (32 patients from which 19 pre- and 43 post-PDT biopsies were taken) were investigated for immune cell infiltration and HLA class I expression by immunohistochemistry and HPV infection by PCR. There was a greater likelihood of HPV positivity associated with a lack of response of VIN to PDT (P = 0.002), and VIN nonresponders were more likely to show HLA class I loss compared with responders (P = 0.030). HLA class I down-regulation was significantly greater in the carcinomas (82%, total loss) than the VIN (28%, 19%, total loss; and 9%, allele loss; P = 0.004). None of the cases with class I down-regulation responded to PDT, whereas 3 of 6 (50%) of cases that showed total class I loss subsequently developed superficial invasion. Compared with normal vulval skin, VIN lesions showed increased infiltration by CD4 (T-helper) and CD68 (macrophages) but not CD1a (Langerhans cells) or CD8 (CTLs). There was, however, a significant increase of CD8 infiltration in posttreatment VIN responders compared with nonresponders (P = 0.0001). These data clearly support the contention that high-risk HPV infection and lack of cell-mediated immunity may play a role in the observed poor response of lower genital lesions to topical PDT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Photodynamic therapy: a new antimicrobial approach to infectious disease?

Authors:  Michael R Hamblin; Tayyaba Hasan
Journal:  Photochem Photobiol Sci       Date:  2004-02-12       Impact factor: 3.982

Review 3.  Photodynamic therapy targeted to pathogens.

Authors:  T N Demidova; M R Hamblin
Journal:  Int J Immunopathol Pharmacol       Date:  2004 Sep-Dec       Impact factor: 3.219

Review 4.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 5.  The application of physical pretreatment in photodynamic therapy for skin diseases.

Authors:  Dihui Liu; Shuang Zhao; Jinmao Li; Mingliang Chen; Lisha Wu
Journal:  Lasers Med Sci       Date:  2021-01-06       Impact factor: 3.161

6.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

7.  Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

Authors:  S Daayana; E Elkord; U Winters; M Pawlita; R Roden; P L Stern; H C Kitchener
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

Review 8.  Photodynamic therapy for localized infections--state of the art.

Authors:  Tianhong Dai; Ying-Ying Huang; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2009 Sep-Dec       Impact factor: 3.631

Review 9.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

Review 10.  Enhancement of anti-tumor immunity by photodynamic therapy.

Authors:  Sandra O Gollnick; Craig M Brackett
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.